Clarke says the prescription drug landscape is changing and it would benefit plan sponsors to think long term when it comes to developing a cost management strategy. ???The number of biologic drugs in the pipeline is increasing???which is great news for those suffering from chronic conditions such as rheumatoid arthritis, multiple sclerosis, Crohn???s disease and lupus.